nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP2B6—Thiotepa—sarcoma	0.196	0.333	CbGbCtD
Loperamide—CYP3A4—Thiotepa—sarcoma	0.0601	0.102	CbGbCtD
Loperamide—ABCB1—Dactinomycin—sarcoma	0.0482	0.0821	CbGbCtD
Loperamide—ABCB1—Mitoxantrone—sarcoma	0.0431	0.0734	CbGbCtD
Loperamide—CYP2C8—Etoposide—sarcoma	0.0402	0.0684	CbGbCtD
Loperamide—CYP2B6—Doxorubicin—sarcoma	0.0362	0.0616	CbGbCtD
Loperamide—ABCB1—Vincristine—sarcoma	0.0297	0.0505	CbGbCtD
Loperamide—ABCB1—Etoposide—sarcoma	0.0272	0.0463	CbGbCtD
Loperamide—CYP3A4—Mitoxantrone—sarcoma	0.0258	0.044	CbGbCtD
Loperamide—ABCB1—Doxorubicin—sarcoma	0.0186	0.0316	CbGbCtD
Loperamide—CYP3A4—Vincristine—sarcoma	0.0178	0.0303	CbGbCtD
Loperamide—CYP2D6—Doxorubicin—sarcoma	0.0175	0.0298	CbGbCtD
Loperamide—CYP3A4—Etoposide—sarcoma	0.0163	0.0277	CbGbCtD
Loperamide—Abdominal colic—Vincristine—sarcoma	0.0133	0.107	CcSEcCtD
Loperamide—CYP3A4—Doxorubicin—sarcoma	0.0111	0.0189	CbGbCtD
Loperamide—Ileus paralytic—Vincristine—sarcoma	0.00415	0.0334	CcSEcCtD
Loperamide—Altered state of consciousness—Vincristine—sarcoma	0.00389	0.0313	CcSEcCtD
Loperamide—POMC—hematopoietic system—sarcoma	0.0038	0.0509	CbGeAlD
Loperamide—POMC—connective tissue—sarcoma	0.00366	0.049	CbGeAlD
Loperamide—Epigastric pain—Mitoxantrone—sarcoma	0.00361	0.0291	CcSEcCtD
Loperamide—POMC—skin of body—sarcoma	0.00331	0.0442	CbGeAlD
Loperamide—Ileus—Thiotepa—sarcoma	0.00286	0.023	CcSEcCtD
Loperamide—POMC—lymphoid tissue—sarcoma	0.00268	0.0358	CbGeAlD
Loperamide—Abdominal cramps—Vincristine—sarcoma	0.00266	0.0214	CcSEcCtD
Loperamide—Ileus—Vincristine—sarcoma	0.00253	0.0204	CcSEcCtD
Loperamide—CALM3—mammary gland—sarcoma	0.00217	0.029	CbGeAlD
Loperamide—CALM2—endothelium—sarcoma	0.00211	0.0283	CbGeAlD
Loperamide—CALM1—endothelium—sarcoma	0.0021	0.0282	CbGeAlD
Loperamide—POMC—testis—sarcoma	0.00208	0.0279	CbGeAlD
Loperamide—Bullous eruption—Epirubicin—sarcoma	0.00206	0.0166	CcSEcCtD
Loperamide—CACNA1A—testis—sarcoma	0.00199	0.0266	CbGeAlD
Loperamide—POMC—liver—sarcoma	0.00197	0.0264	CbGeAlD
Loperamide—Bullous eruption—Doxorubicin—sarcoma	0.00191	0.0154	CcSEcCtD
Loperamide—CALM1—mammary gland—sarcoma	0.0017	0.0227	CbGeAlD
Loperamide—CALM3—myometrium—sarcoma	0.00154	0.0206	CbGeAlD
Loperamide—OPRM1—hematopoietic system—sarcoma	0.00143	0.0191	CbGeAlD
Loperamide—CYP2C8—mammary gland—sarcoma	0.00141	0.0189	CbGeAlD
Loperamide—Urinary retention—Thiotepa—sarcoma	0.0014	0.0113	CcSEcCtD
Loperamide—CALM3—seminal vesicle—sarcoma	0.00139	0.0186	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Dactinomycin—sarcoma	0.00131	0.0106	CcSEcCtD
Loperamide—Anaphylactoid reaction—Mitoxantrone—sarcoma	0.00131	0.0106	CcSEcCtD
Loperamide—Urinary retention—Vincristine—sarcoma	0.00124	0.00998	CcSEcCtD
Loperamide—CALM2—myometrium—sarcoma	0.00121	0.0162	CbGeAlD
Loperamide—CALM1—myometrium—sarcoma	0.0012	0.0161	CbGeAlD
Loperamide—CALM3—smooth muscle tissue—sarcoma	0.00116	0.0156	CbGeAlD
Loperamide—CALM2—embryo—sarcoma	0.00116	0.0156	CbGeAlD
Loperamide—Abdominal pain upper—Mitoxantrone—sarcoma	0.00116	0.00933	CcSEcCtD
Loperamide—CALM1—embryo—sarcoma	0.00116	0.0155	CbGeAlD
Loperamide—Ileus—Epirubicin—sarcoma	0.00115	0.00927	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Dactinomycin—sarcoma	0.00111	0.00897	CcSEcCtD
Loperamide—CALM2—seminal vesicle—sarcoma	0.00109	0.0146	CbGeAlD
Loperamide—Anaphylactoid reaction—Etoposide—sarcoma	0.00109	0.00878	CcSEcCtD
Loperamide—Ileus—Doxorubicin—sarcoma	0.00106	0.00858	CcSEcCtD
Loperamide—CALM2—hematopoietic system—sarcoma	0.00104	0.0139	CbGeAlD
Loperamide—CALM1—hematopoietic system—sarcoma	0.00103	0.0138	CbGeAlD
Loperamide—CALM3—cardiac atrium—sarcoma	0.001	0.0134	CbGeAlD
Loperamide—Urinary tract disorder—Thiotepa—sarcoma	0.001	0.00808	CcSEcCtD
Loperamide—CALM2—connective tissue—sarcoma	0.001	0.0134	CbGeAlD
Loperamide—CALM3—uterus—sarcoma	0.000999	0.0134	CbGeAlD
Loperamide—Urethral disorder—Thiotepa—sarcoma	0.000996	0.00802	CcSEcCtD
Loperamide—CALM1—connective tissue—sarcoma	0.000995	0.0133	CbGeAlD
Loperamide—Drowsiness—Mitoxantrone—sarcoma	0.000977	0.00787	CcSEcCtD
Loperamide—Erythema multiforme—Dactinomycin—sarcoma	0.000953	0.00768	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Etoposide—sarcoma	0.00095	0.00765	CcSEcCtD
Loperamide—Immune system disorder—Thiotepa—sarcoma	0.000918	0.00739	CcSEcCtD
Loperamide—CALM2—smooth muscle tissue—sarcoma	0.000914	0.0122	CbGeAlD
Loperamide—CALM1—smooth muscle tissue—sarcoma	0.00091	0.0122	CbGeAlD
Loperamide—CALM2—skin of body—sarcoma	0.000903	0.0121	CbGeAlD
Loperamide—CALM1—skin of body—sarcoma	0.000899	0.012	CbGeAlD
Loperamide—Urinary tract disorder—Vincristine—sarcoma	0.00089	0.00717	CcSEcCtD
Loperamide—Urethral disorder—Vincristine—sarcoma	0.000883	0.00712	CcSEcCtD
Loperamide—CALM3—tendon—sarcoma	0.000875	0.0117	CbGeAlD
Loperamide—CYP2C8—hematopoietic system—sarcoma	0.000861	0.0115	CbGeAlD
Loperamide—CALM3—bone marrow—sarcoma	0.000848	0.0113	CbGeAlD
Loperamide—Stevens-Johnson syndrome—Etoposide—sarcoma	0.000806	0.00649	CcSEcCtD
Loperamide—CALM2—cardiac atrium—sarcoma	0.000788	0.0106	CbGeAlD
Loperamide—CALM1—cardiac atrium—sarcoma	0.000785	0.0105	CbGeAlD
Loperamide—CALM2—uterus—sarcoma	0.000784	0.0105	CbGeAlD
Loperamide—OPRM1—testis—sarcoma	0.000784	0.0105	CbGeAlD
Loperamide—CALM1—uterus—sarcoma	0.000781	0.0104	CbGeAlD
Loperamide—CYP2B6—hematopoietic system—sarcoma	0.000772	0.0103	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000748	0.00602	CcSEcCtD
Loperamide—Discomfort—Dactinomycin—sarcoma	0.000738	0.00595	CcSEcCtD
Loperamide—CALM2—lymphoid tissue—sarcoma	0.000731	0.00978	CbGeAlD
Loperamide—CALM1—lymphoid tissue—sarcoma	0.000728	0.00974	CbGeAlD
Loperamide—CALM3—testis—sarcoma	0.000725	0.0097	CbGeAlD
Loperamide—Urinary tract disorder—Etoposide—sarcoma	0.000721	0.00581	CcSEcCtD
Loperamide—Urethral disorder—Etoposide—sarcoma	0.000715	0.00576	CcSEcCtD
Loperamide—Nervous system disorder—Thiotepa—sarcoma	0.000708	0.0057	CcSEcCtD
Loperamide—Skin disorder—Thiotepa—sarcoma	0.000701	0.00565	CcSEcCtD
Loperamide—Erythema multiforme—Etoposide—sarcoma	0.00069	0.00556	CcSEcCtD
Loperamide—CALM2—tendon—sarcoma	0.000687	0.0092	CbGeAlD
Loperamide—CALM3—liver—sarcoma	0.000685	0.00917	CbGeAlD
Loperamide—CALM1—tendon—sarcoma	0.000684	0.00915	CbGeAlD
Loperamide—CYP2B6—skin of body—sarcoma	0.000671	0.00898	CbGeAlD
Loperamide—CALM2—bone marrow—sarcoma	0.000666	0.00891	CbGeAlD
Loperamide—CALM1—bone marrow—sarcoma	0.000663	0.00887	CbGeAlD
Loperamide—Immune system disorder—Etoposide—sarcoma	0.000659	0.00531	CcSEcCtD
Loperamide—Discomfort—Mitoxantrone—sarcoma	0.000642	0.00518	CcSEcCtD
Loperamide—Somnolence—Thiotepa—sarcoma	0.000642	0.00517	CcSEcCtD
Loperamide—Anaphylactic shock—Vincristine—sarcoma	0.00064	0.00516	CcSEcCtD
Loperamide—Dyspepsia—Thiotepa—sarcoma	0.000635	0.00512	CcSEcCtD
Loperamide—Nervous system disorder—Vincristine—sarcoma	0.000628	0.00506	CcSEcCtD
Loperamide—Anaphylactic shock—Mitoxantrone—sarcoma	0.000623	0.00502	CcSEcCtD
Loperamide—Gastrointestinal disorder—Thiotepa—sarcoma	0.000623	0.00502	CcSEcCtD
Loperamide—Fatigue—Thiotepa—sarcoma	0.000622	0.00501	CcSEcCtD
Loperamide—Dermatitis bullous—Epirubicin—sarcoma	0.000619	0.00499	CcSEcCtD
Loperamide—Fatigue—Dactinomycin—sarcoma	0.000618	0.00498	CcSEcCtD
Loperamide—Constipation—Thiotepa—sarcoma	0.000617	0.00497	CcSEcCtD
Loperamide—Anaphylactoid reaction—Epirubicin—sarcoma	0.000611	0.00492	CcSEcCtD
Loperamide—Skin disorder—Mitoxantrone—sarcoma	0.000605	0.00488	CcSEcCtD
Loperamide—Gastrointestinal pain—Thiotepa—sarcoma	0.00059	0.00476	CcSEcCtD
Loperamide—Gastrointestinal pain—Dactinomycin—sarcoma	0.000586	0.00472	CcSEcCtD
Loperamide—CYP3A4—hematopoietic system—sarcoma	0.000583	0.0078	CbGeAlD
Loperamide—CYP2D6—hematopoietic system—sarcoma	0.000574	0.00768	CbGeAlD
Loperamide—Urticaria—Thiotepa—sarcoma	0.000573	0.00462	CcSEcCtD
Loperamide—Dermatitis bullous—Doxorubicin—sarcoma	0.000572	0.00461	CcSEcCtD
Loperamide—Abdominal pain—Thiotepa—sarcoma	0.000571	0.0046	CcSEcCtD
Loperamide—CALM2—testis—sarcoma	0.000569	0.00762	CbGeAlD
Loperamide—CALM1—testis—sarcoma	0.000566	0.00758	CbGeAlD
Loperamide—Abdominal pain—Dactinomycin—sarcoma	0.000566	0.00456	CcSEcCtD
Loperamide—Anaphylactoid reaction—Doxorubicin—sarcoma	0.000565	0.00455	CcSEcCtD
Loperamide—Loss of consciousness—Etoposide—sarcoma	0.000558	0.0045	CcSEcCtD
Loperamide—Somnolence—Mitoxantrone—sarcoma	0.000554	0.00446	CcSEcCtD
Loperamide—Gastrointestinal disorder—Vincristine—sarcoma	0.000553	0.00445	CcSEcCtD
Loperamide—Fatigue—Vincristine—sarcoma	0.000552	0.00445	CcSEcCtD
Loperamide—Dyspepsia—Mitoxantrone—sarcoma	0.000549	0.00442	CcSEcCtD
Loperamide—Constipation—Vincristine—sarcoma	0.000547	0.00441	CcSEcCtD
Loperamide—CYP2B6—lymphoid tissue—sarcoma	0.000543	0.00727	CbGeAlD
Loperamide—Abdominal pain upper—Epirubicin—sarcoma	0.00054	0.00435	CcSEcCtD
Loperamide—CALM2—liver—sarcoma	0.000538	0.0072	CbGeAlD
Loperamide—Fatigue—Mitoxantrone—sarcoma	0.000537	0.00433	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000537	0.00433	CcSEcCtD
Loperamide—CALM1—liver—sarcoma	0.000535	0.00717	CbGeAlD
Loperamide—Discomfort—Etoposide—sarcoma	0.000534	0.00431	CcSEcCtD
Loperamide—Constipation—Mitoxantrone—sarcoma	0.000533	0.00429	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.000532	0.00429	CcSEcCtD
Loperamide—Hypersensitivity—Thiotepa—sarcoma	0.000532	0.00428	CcSEcCtD
Loperamide—Hypersensitivity—Dactinomycin—sarcoma	0.000528	0.00425	CcSEcCtD
Loperamide—CALM3—lymph node—sarcoma	0.000525	0.00703	CbGeAlD
Loperamide—Gastrointestinal pain—Vincristine—sarcoma	0.000523	0.00422	CcSEcCtD
Loperamide—Anaphylactic shock—Etoposide—sarcoma	0.000518	0.00418	CcSEcCtD
Loperamide—Asthenia—Thiotepa—sarcoma	0.000518	0.00417	CcSEcCtD
Loperamide—Abdominal distension—Epirubicin—sarcoma	0.000515	0.00415	CcSEcCtD
Loperamide—Asthenia—Dactinomycin—sarcoma	0.000514	0.00414	CcSEcCtD
Loperamide—Pruritus—Thiotepa—sarcoma	0.000511	0.00411	CcSEcCtD
Loperamide—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00051	0.00411	CcSEcCtD
Loperamide—Abdominal pain—Vincristine—sarcoma	0.000506	0.00408	CcSEcCtD
Loperamide—Skin disorder—Etoposide—sarcoma	0.000504	0.00406	CcSEcCtD
Loperamide—Abdominal pain upper—Doxorubicin—sarcoma	0.0005	0.00403	CcSEcCtD
Loperamide—Urticaria—Mitoxantrone—sarcoma	0.000495	0.00399	CcSEcCtD
Loperamide—Diarrhoea—Thiotepa—sarcoma	0.000494	0.00398	CcSEcCtD
Loperamide—Abdominal pain—Mitoxantrone—sarcoma	0.000493	0.00397	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000493	0.00397	CcSEcCtD
Loperamide—Diarrhoea—Dactinomycin—sarcoma	0.00049	0.00395	CcSEcCtD
Loperamide—ABCB1—myometrium—sarcoma	0.000481	0.00643	CbGeAlD
Loperamide—Dizziness—Thiotepa—sarcoma	0.000477	0.00385	CcSEcCtD
Loperamide—Abdominal distension—Doxorubicin—sarcoma	0.000476	0.00384	CcSEcCtD
Loperamide—CYP2C8—testis—sarcoma	0.000472	0.00631	CbGeAlD
Loperamide—Hypersensitivity—Vincristine—sarcoma	0.000472	0.0038	CcSEcCtD
Loperamide—ABCB1—embryo—sarcoma	0.000462	0.00619	CbGeAlD
Loperamide—Somnolence—Etoposide—sarcoma	0.000461	0.00371	CcSEcCtD
Loperamide—Hypersensitivity—Mitoxantrone—sarcoma	0.000459	0.0037	CcSEcCtD
Loperamide—Asthenia—Vincristine—sarcoma	0.000459	0.0037	CcSEcCtD
Loperamide—Vomiting—Thiotepa—sarcoma	0.000459	0.0037	CcSEcCtD
Loperamide—Drowsiness—Epirubicin—sarcoma	0.000456	0.00367	CcSEcCtD
Loperamide—Vomiting—Dactinomycin—sarcoma	0.000455	0.00367	CcSEcCtD
Loperamide—Rash—Thiotepa—sarcoma	0.000455	0.00367	CcSEcCtD
Loperamide—Dermatitis—Thiotepa—sarcoma	0.000455	0.00366	CcSEcCtD
Loperamide—Headache—Thiotepa—sarcoma	0.000452	0.00364	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000452	0.00364	CcSEcCtD
Loperamide—Rash—Dactinomycin—sarcoma	0.000452	0.00364	CcSEcCtD
Loperamide—Gastrointestinal disorder—Etoposide—sarcoma	0.000448	0.00361	CcSEcCtD
Loperamide—Asthenia—Mitoxantrone—sarcoma	0.000447	0.0036	CcSEcCtD
Loperamide—Fatigue—Etoposide—sarcoma	0.000447	0.0036	CcSEcCtD
Loperamide—CYP2C8—liver—sarcoma	0.000446	0.00597	CbGeAlD
Loperamide—Constipation—Etoposide—sarcoma	0.000443	0.00357	CcSEcCtD
Loperamide—Diarrhoea—Vincristine—sarcoma	0.000438	0.00353	CcSEcCtD
Loperamide—ABCB1—seminal vesicle—sarcoma	0.000434	0.00581	CbGeAlD
Loperamide—Nausea—Thiotepa—sarcoma	0.000429	0.00345	CcSEcCtD
Loperamide—Diarrhoea—Mitoxantrone—sarcoma	0.000426	0.00344	CcSEcCtD
Loperamide—Nausea—Dactinomycin—sarcoma	0.000426	0.00343	CcSEcCtD
Loperamide—Gastrointestinal pain—Etoposide—sarcoma	0.000424	0.00342	CcSEcCtD
Loperamide—Dizziness—Vincristine—sarcoma	0.000423	0.00341	CcSEcCtD
Loperamide—CYP2B6—testis—sarcoma	0.000423	0.00566	CbGeAlD
Loperamide—Drowsiness—Doxorubicin—sarcoma	0.000422	0.0034	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000418	0.00337	CcSEcCtD
Loperamide—ABCB1—hematopoietic system—sarcoma	0.000413	0.00552	CbGeAlD
Loperamide—CALM2—lymph node—sarcoma	0.000412	0.00552	CbGeAlD
Loperamide—Urticaria—Etoposide—sarcoma	0.000412	0.00332	CcSEcCtD
Loperamide—CALM1—lymph node—sarcoma	0.000411	0.00549	CbGeAlD
Loperamide—Abdominal pain—Etoposide—sarcoma	0.00041	0.0033	CcSEcCtD
Loperamide—Vomiting—Vincristine—sarcoma	0.000407	0.00328	CcSEcCtD
Loperamide—Urinary tract disorder—Epirubicin—sarcoma	0.000404	0.00326	CcSEcCtD
Loperamide—Rash—Vincristine—sarcoma	0.000404	0.00325	CcSEcCtD
Loperamide—Dermatitis—Vincristine—sarcoma	0.000403	0.00325	CcSEcCtD
Loperamide—Urethral disorder—Epirubicin—sarcoma	0.000401	0.00323	CcSEcCtD
Loperamide—Headache—Vincristine—sarcoma	0.000401	0.00323	CcSEcCtD
Loperamide—CYP2B6—liver—sarcoma	0.0004	0.00535	CbGeAlD
Loperamide—Vomiting—Mitoxantrone—sarcoma	0.000396	0.00319	CcSEcCtD
Loperamide—Rash—Mitoxantrone—sarcoma	0.000393	0.00317	CcSEcCtD
Loperamide—Dermatitis—Mitoxantrone—sarcoma	0.000393	0.00316	CcSEcCtD
Loperamide—Headache—Mitoxantrone—sarcoma	0.00039	0.00315	CcSEcCtD
Loperamide—Erythema multiforme—Epirubicin—sarcoma	0.000387	0.00312	CcSEcCtD
Loperamide—Hypersensitivity—Etoposide—sarcoma	0.000382	0.00308	CcSEcCtD
Loperamide—Nausea—Vincristine—sarcoma	0.00038	0.00306	CcSEcCtD
Loperamide—Urinary tract disorder—Doxorubicin—sarcoma	0.000374	0.00301	CcSEcCtD
Loperamide—Asthenia—Etoposide—sarcoma	0.000372	0.003	CcSEcCtD
Loperamide—Urethral disorder—Doxorubicin—sarcoma	0.000371	0.00299	CcSEcCtD
Loperamide—Nausea—Mitoxantrone—sarcoma	0.00037	0.00298	CcSEcCtD
Loperamide—Immune system disorder—Epirubicin—sarcoma	0.000369	0.00298	CcSEcCtD
Loperamide—Pruritus—Etoposide—sarcoma	0.000367	0.00296	CcSEcCtD
Loperamide—Erythema multiforme—Doxorubicin—sarcoma	0.000358	0.00288	CcSEcCtD
Loperamide—Diarrhoea—Etoposide—sarcoma	0.000355	0.00286	CcSEcCtD
Loperamide—Flatulence—Epirubicin—sarcoma	0.000351	0.00283	CcSEcCtD
Loperamide—Dizziness—Etoposide—sarcoma	0.000343	0.00276	CcSEcCtD
Loperamide—Immune system disorder—Doxorubicin—sarcoma	0.000342	0.00275	CcSEcCtD
Loperamide—Vomiting—Etoposide—sarcoma	0.00033	0.00266	CcSEcCtD
Loperamide—Rash—Etoposide—sarcoma	0.000327	0.00263	CcSEcCtD
Loperamide—Dermatitis—Etoposide—sarcoma	0.000327	0.00263	CcSEcCtD
Loperamide—Headache—Etoposide—sarcoma	0.000325	0.00262	CcSEcCtD
Loperamide—Flatulence—Doxorubicin—sarcoma	0.000325	0.00262	CcSEcCtD
Loperamide—CYP2D6—testis—sarcoma	0.000314	0.00421	CbGeAlD
Loperamide—Loss of consciousness—Epirubicin—sarcoma	0.000313	0.00252	CcSEcCtD
Loperamide—ABCB1—uterus—sarcoma	0.000312	0.00417	CbGeAlD
Loperamide—Nausea—Etoposide—sarcoma	0.000308	0.00248	CcSEcCtD
Loperamide—CYP3A4—liver—sarcoma	0.000302	0.00404	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000301	0.00243	CcSEcCtD
Loperamide—Discomfort—Epirubicin—sarcoma	0.0003	0.00241	CcSEcCtD
Loperamide—CYP2D6—liver—sarcoma	0.000297	0.00398	CbGeAlD
Loperamide—Dry mouth—Epirubicin—sarcoma	0.000297	0.00239	CcSEcCtD
Loperamide—Anaphylactic shock—Epirubicin—sarcoma	0.000291	0.00234	CcSEcCtD
Loperamide—ABCB1—lymphoid tissue—sarcoma	0.00029	0.00389	CbGeAlD
Loperamide—Loss of consciousness—Doxorubicin—sarcoma	0.00029	0.00233	CcSEcCtD
Loperamide—Nervous system disorder—Epirubicin—sarcoma	0.000285	0.0023	CcSEcCtD
Loperamide—Skin disorder—Epirubicin—sarcoma	0.000282	0.00227	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000279	0.00224	CcSEcCtD
Loperamide—Discomfort—Doxorubicin—sarcoma	0.000277	0.00223	CcSEcCtD
Loperamide—Dry mouth—Doxorubicin—sarcoma	0.000274	0.00221	CcSEcCtD
Loperamide—Anaphylactic shock—Doxorubicin—sarcoma	0.000269	0.00217	CcSEcCtD
Loperamide—ABCB1—bone marrow—sarcoma	0.000264	0.00354	CbGeAlD
Loperamide—Nervous system disorder—Doxorubicin—sarcoma	0.000264	0.00212	CcSEcCtD
Loperamide—Skin disorder—Doxorubicin—sarcoma	0.000261	0.0021	CcSEcCtD
Loperamide—Somnolence—Epirubicin—sarcoma	0.000258	0.00208	CcSEcCtD
Loperamide—Dyspepsia—Epirubicin—sarcoma	0.000256	0.00206	CcSEcCtD
Loperamide—Gastrointestinal disorder—Epirubicin—sarcoma	0.000251	0.00202	CcSEcCtD
Loperamide—Fatigue—Epirubicin—sarcoma	0.000251	0.00202	CcSEcCtD
Loperamide—Constipation—Epirubicin—sarcoma	0.000249	0.002	CcSEcCtD
Loperamide—Somnolence—Doxorubicin—sarcoma	0.000239	0.00193	CcSEcCtD
Loperamide—Gastrointestinal pain—Epirubicin—sarcoma	0.000238	0.00191	CcSEcCtD
Loperamide—Dyspepsia—Doxorubicin—sarcoma	0.000237	0.00191	CcSEcCtD
Loperamide—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000232	0.00187	CcSEcCtD
Loperamide—Fatigue—Doxorubicin—sarcoma	0.000232	0.00187	CcSEcCtD
Loperamide—Urticaria—Epirubicin—sarcoma	0.000231	0.00186	CcSEcCtD
Loperamide—Constipation—Doxorubicin—sarcoma	0.00023	0.00185	CcSEcCtD
Loperamide—Abdominal pain—Epirubicin—sarcoma	0.00023	0.00185	CcSEcCtD
Loperamide—ABCB1—testis—sarcoma	0.000226	0.00303	CbGeAlD
Loperamide—Gastrointestinal pain—Doxorubicin—sarcoma	0.00022	0.00177	CcSEcCtD
Loperamide—Hypersensitivity—Epirubicin—sarcoma	0.000214	0.00173	CcSEcCtD
Loperamide—ABCB1—liver—sarcoma	0.000214	0.00286	CbGeAlD
Loperamide—Urticaria—Doxorubicin—sarcoma	0.000214	0.00172	CcSEcCtD
Loperamide—Abdominal pain—Doxorubicin—sarcoma	0.000213	0.00171	CcSEcCtD
Loperamide—Asthenia—Epirubicin—sarcoma	0.000209	0.00168	CcSEcCtD
Loperamide—Pruritus—Epirubicin—sarcoma	0.000206	0.00166	CcSEcCtD
Loperamide—Diarrhoea—Epirubicin—sarcoma	0.000199	0.0016	CcSEcCtD
Loperamide—Hypersensitivity—Doxorubicin—sarcoma	0.000198	0.0016	CcSEcCtD
Loperamide—Asthenia—Doxorubicin—sarcoma	0.000193	0.00155	CcSEcCtD
Loperamide—Dizziness—Epirubicin—sarcoma	0.000192	0.00155	CcSEcCtD
Loperamide—Pruritus—Doxorubicin—sarcoma	0.00019	0.00153	CcSEcCtD
Loperamide—Vomiting—Epirubicin—sarcoma	0.000185	0.00149	CcSEcCtD
Loperamide—Diarrhoea—Doxorubicin—sarcoma	0.000184	0.00148	CcSEcCtD
Loperamide—Rash—Epirubicin—sarcoma	0.000183	0.00148	CcSEcCtD
Loperamide—Dermatitis—Epirubicin—sarcoma	0.000183	0.00148	CcSEcCtD
Loperamide—Headache—Epirubicin—sarcoma	0.000182	0.00147	CcSEcCtD
Loperamide—Dizziness—Doxorubicin—sarcoma	0.000178	0.00143	CcSEcCtD
Loperamide—Nausea—Epirubicin—sarcoma	0.000173	0.00139	CcSEcCtD
Loperamide—Vomiting—Doxorubicin—sarcoma	0.000171	0.00138	CcSEcCtD
Loperamide—Rash—Doxorubicin—sarcoma	0.00017	0.00137	CcSEcCtD
Loperamide—Dermatitis—Doxorubicin—sarcoma	0.000169	0.00136	CcSEcCtD
Loperamide—Headache—Doxorubicin—sarcoma	0.000168	0.00136	CcSEcCtD
Loperamide—ABCB1—lymph node—sarcoma	0.000164	0.00219	CbGeAlD
Loperamide—Nausea—Doxorubicin—sarcoma	0.00016	0.00129	CcSEcCtD
Loperamide—CALM2—Innate Immune System—JUN—sarcoma	2.58e-05	0.000121	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ATF1—sarcoma	2.58e-05	0.000121	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KDR—sarcoma	2.57e-05	0.00012	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—SRC—sarcoma	2.57e-05	0.00012	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—SRC—sarcoma	2.57e-05	0.00012	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—CTNNB1—sarcoma	2.56e-05	0.00012	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—CTNNB1—sarcoma	2.56e-05	0.00012	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—NRAS—sarcoma	2.55e-05	0.000119	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—EGFR—sarcoma	2.55e-05	0.000119	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCR4—sarcoma	2.52e-05	0.000118	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCR4—sarcoma	2.52e-05	0.000118	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MDM2—sarcoma	2.52e-05	0.000118	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—VEGFA—sarcoma	2.5e-05	0.000117	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—VEGFA—sarcoma	2.5e-05	0.000117	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ATF1—sarcoma	2.49e-05	0.000117	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ATF1—sarcoma	2.49e-05	0.000117	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—NRAS—sarcoma	2.47e-05	0.000116	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—NRAS—sarcoma	2.47e-05	0.000116	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PLCG1—sarcoma	2.46e-05	0.000115	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—KRAS—sarcoma	2.41e-05	0.000113	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—SRC—sarcoma	2.39e-05	0.000112	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KIT—sarcoma	2.37e-05	0.000111	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—NRAS—sarcoma	2.37e-05	0.000111	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CREB1—sarcoma	2.36e-05	0.000111	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—HRAS—sarcoma	2.34e-05	0.000109	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PLCG1—sarcoma	2.32e-05	0.000108	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—SRC—sarcoma	2.31e-05	0.000108	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—SRC—sarcoma	2.31e-05	0.000108	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—NRAS—sarcoma	2.3e-05	0.000108	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—SRC—sarcoma	2.3e-05	0.000107	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CREB1—sarcoma	2.29e-05	0.000107	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CREB1—sarcoma	2.29e-05	0.000107	CbGpPWpGaD
Loperamide—CALM3—Immune System—KIT—sarcoma	2.27e-05	0.000106	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CREB1—sarcoma	2.25e-05	0.000105	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL2—sarcoma	2.25e-05	0.000105	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—NRAS—sarcoma	2.22e-05	0.000104	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—NRAS—sarcoma	2.22e-05	0.000104	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—SRC—sarcoma	2.22e-05	0.000104	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—SRC—sarcoma	2.22e-05	0.000104	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—NRAS—sarcoma	2.21e-05	0.000103	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MDM2—sarcoma	2.21e-05	0.000103	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—KRAS—sarcoma	2.2e-05	0.000103	CbGpPWpGaD
Loperamide—CALM2—Immune System—KIT—sarcoma	2.19e-05	0.000103	CbGpPWpGaD
Loperamide—CALM1—Immune System—KIT—sarcoma	2.19e-05	0.000103	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CCND1—sarcoma	2.19e-05	0.000103	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—JUN—sarcoma	2.19e-05	0.000102	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CTNNB1—sarcoma	2.17e-05	0.000102	CbGpPWpGaD
Loperamide—CALM3—Immune System—CREB1—sarcoma	2.16e-05	0.000101	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—EGFR—sarcoma	2.16e-05	0.000101	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—NRAS—sarcoma	2.14e-05	9.99e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—NRAS—sarcoma	2.14e-05	9.99e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—KRAS—sarcoma	2.13e-05	9.95e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—KRAS—sarcoma	2.13e-05	9.95e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—EGFR—sarcoma	2.1e-05	9.8e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—KIT—sarcoma	2.09e-05	9.79e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CREB1—sarcoma	2.09e-05	9.77e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CREB1—sarcoma	2.09e-05	9.77e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—HRAS—sarcoma	2.05e-05	9.59e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—KRAS—sarcoma	2.04e-05	9.54e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—EGFR—sarcoma	2.03e-05	9.48e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—EGFR—sarcoma	2.03e-05	9.48e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—KIT—sarcoma	2.03e-05	9.47e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—KIT—sarcoma	2.03e-05	9.47e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IGF1R—sarcoma	2.02e-05	9.46e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—EGFR—sarcoma	2.01e-05	9.41e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CREB1—sarcoma	1.99e-05	9.32e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—KRAS—sarcoma	1.98e-05	9.26e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL2—sarcoma	1.97e-05	9.22e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—SRC—sarcoma	1.96e-05	9.18e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IGF1R—sarcoma	1.96e-05	9.15e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IGF1R—sarcoma	1.96e-05	9.15e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TP53—sarcoma	1.95e-05	9.14e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—EGFR—sarcoma	1.95e-05	9.1e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—EGFR—sarcoma	1.95e-05	9.1e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CREB1—sarcoma	1.93e-05	9.02e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CREB1—sarcoma	1.93e-05	9.02e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FOXO1—sarcoma	1.92e-05	9e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CCND1—sarcoma	1.92e-05	8.99e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PDGFRB—sarcoma	1.92e-05	8.98e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—JUN—sarcoma	1.92e-05	8.97e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—KRAS—sarcoma	1.91e-05	8.96e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—KRAS—sarcoma	1.91e-05	8.96e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—VEGFA—sarcoma	1.91e-05	8.94e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CTNNB1—sarcoma	1.9e-05	8.91e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—KRAS—sarcoma	1.9e-05	8.89e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PDGFRA—sarcoma	1.89e-05	8.84e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TP53—sarcoma	1.89e-05	8.84e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TP53—sarcoma	1.89e-05	8.84e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—NRAS—sarcoma	1.89e-05	8.83e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—HRAS—sarcoma	1.87e-05	8.74e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MDM2—sarcoma	1.87e-05	8.73e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FOXO1—sarcoma	1.86e-05	8.71e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FOXO1—sarcoma	1.86e-05	8.71e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PDGFRB—sarcoma	1.86e-05	8.69e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PDGFRB—sarcoma	1.86e-05	8.69e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—KRAS—sarcoma	1.84e-05	8.6e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—KRAS—sarcoma	1.84e-05	8.6e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PDGFRA—sarcoma	1.83e-05	8.56e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PDGFRA—sarcoma	1.83e-05	8.56e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—HRAS—sarcoma	1.81e-05	8.46e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—HRAS—sarcoma	1.81e-05	8.46e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—MDM2—sarcoma	1.79e-05	8.35e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ENO2—sarcoma	1.78e-05	8.35e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HBA1—sarcoma	1.77e-05	8.3e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MYC—sarcoma	1.76e-05	8.23e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL2—sarcoma	1.75e-05	8.17e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—HRAS—sarcoma	1.73e-05	8.11e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—MDM2—sarcoma	1.73e-05	8.08e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—MDM2—sarcoma	1.73e-05	8.08e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—SRC—sarcoma	1.72e-05	8.05e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—EGFR—sarcoma	1.72e-05	8.05e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL2—sarcoma	1.69e-05	7.9e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL2—sarcoma	1.69e-05	7.9e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HRAS—sarcoma	1.68e-05	7.87e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—VEGFA—sarcoma	1.68e-05	7.84e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL2—sarcoma	1.67e-05	7.8e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—NRAS—sarcoma	1.66e-05	7.74e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MDM2—sarcoma	1.65e-05	7.71e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HRAS—sarcoma	1.63e-05	7.61e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HRAS—sarcoma	1.63e-05	7.61e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—KRAS—sarcoma	1.62e-05	7.6e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CCND1—sarcoma	1.62e-05	7.6e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—JUN—sarcoma	1.62e-05	7.58e-05	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HRAS—sarcoma	1.62e-05	7.56e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CTNNB1—sarcoma	1.61e-05	7.53e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL2—sarcoma	1.6e-05	7.46e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MDM2—sarcoma	1.6e-05	7.46e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MDM2—sarcoma	1.6e-05	7.46e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KDR—sarcoma	1.59e-05	7.44e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HRAS—sarcoma	1.56e-05	7.31e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HRAS—sarcoma	1.56e-05	7.31e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—JUN—sarcoma	1.55e-05	7.26e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL2—sarcoma	1.54e-05	7.22e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL2—sarcoma	1.54e-05	7.22e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MYC—sarcoma	1.54e-05	7.21e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—CTNNB1—sarcoma	1.54e-05	7.21e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KDR—sarcoma	1.54e-05	7.2e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KDR—sarcoma	1.54e-05	7.2e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PLCG1—sarcoma	1.51e-05	7.08e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—EGFR—sarcoma	1.51e-05	7.06e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—JUN—sarcoma	1.5e-05	7.02e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—JUN—sarcoma	1.5e-05	7.02e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CTNNB1—sarcoma	1.49e-05	6.97e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CTNNB1—sarcoma	1.49e-05	6.97e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KIT—sarcoma	1.47e-05	6.86e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—NRAS—sarcoma	1.47e-05	6.86e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—SRC—sarcoma	1.45e-05	6.8e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TP53—sarcoma	1.44e-05	6.76e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—KRAS—sarcoma	1.42e-05	6.66e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CTNNB1—sarcoma	1.42e-05	6.65e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KIT—sarcoma	1.42e-05	6.63e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KIT—sarcoma	1.42e-05	6.63e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—NRAS—sarcoma	1.42e-05	6.63e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—NRAS—sarcoma	1.42e-05	6.63e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—VEGFA—sarcoma	1.42e-05	6.63e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—NRAS—sarcoma	1.4e-05	6.54e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CREB1—sarcoma	1.4e-05	6.53e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—SRC—sarcoma	1.39e-05	6.51e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—HRAS—sarcoma	1.38e-05	6.46e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CTNNB1—sarcoma	1.38e-05	6.44e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CTNNB1—sarcoma	1.38e-05	6.44e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CREB1—sarcoma	1.35e-05	6.31e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CREB1—sarcoma	1.35e-05	6.31e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—SRC—sarcoma	1.35e-05	6.3e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—SRC—sarcoma	1.35e-05	6.3e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—NRAS—sarcoma	1.34e-05	6.27e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—EGFR—sarcoma	1.34e-05	6.25e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MYC—sarcoma	1.3e-05	6.1e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—NRAS—sarcoma	1.3e-05	6.06e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—NRAS—sarcoma	1.3e-05	6.06e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—EGFR—sarcoma	1.29e-05	6.04e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—EGFR—sarcoma	1.29e-05	6.04e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—SRC—sarcoma	1.29e-05	6.01e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—EGFR—sarcoma	1.27e-05	5.96e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—sarcoma	1.27e-05	5.92e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—KRAS—sarcoma	1.26e-05	5.9e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—SRC—sarcoma	1.24e-05	5.82e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—SRC—sarcoma	1.24e-05	5.82e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—NRAS—sarcoma	1.24e-05	5.79e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—KRAS—sarcoma	1.22e-05	5.71e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—KRAS—sarcoma	1.22e-05	5.71e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—EGFR—sarcoma	1.22e-05	5.71e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HRAS—sarcoma	1.21e-05	5.67e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KRAS—sarcoma	1.2e-05	5.63e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—NRAS—sarcoma	1.2e-05	5.6e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—NRAS—sarcoma	1.2e-05	5.6e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—EGFR—sarcoma	1.18e-05	5.52e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—EGFR—sarcoma	1.18e-05	5.52e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MDM2—sarcoma	1.15e-05	5.4e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—KRAS—sarcoma	1.15e-05	5.39e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MYC—sarcoma	1.15e-05	5.39e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—EGFR—sarcoma	1.13e-05	5.27e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MDM2—sarcoma	1.12e-05	5.22e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MDM2—sarcoma	1.12e-05	5.22e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—KRAS—sarcoma	1.12e-05	5.22e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—KRAS—sarcoma	1.12e-05	5.22e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MYC—sarcoma	1.11e-05	5.21e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MYC—sarcoma	1.11e-05	5.21e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—EGFR—sarcoma	1.09e-05	5.1e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—EGFR—sarcoma	1.09e-05	5.1e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—HRAS—sarcoma	1.07e-05	5.02e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—sarcoma	1.07e-05	5.01e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—KRAS—sarcoma	1.06e-05	4.98e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—HRAS—sarcoma	1.04e-05	4.85e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—HRAS—sarcoma	1.04e-05	4.85e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL2—sarcoma	1.03e-05	4.83e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—KRAS—sarcoma	1.03e-05	4.82e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—KRAS—sarcoma	1.03e-05	4.82e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HRAS—sarcoma	1.02e-05	4.79e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCND1—sarcoma	1.01e-05	4.7e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—JUN—sarcoma	1e-05	4.69e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL2—sarcoma	9.98e-06	4.67e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL2—sarcoma	9.98e-06	4.67e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CTNNB1—sarcoma	9.96e-06	4.66e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—HRAS—sarcoma	9.8e-06	4.58e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCND1—sarcoma	9.73e-06	4.55e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCND1—sarcoma	9.73e-06	4.55e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—JUN—sarcoma	9.71e-06	4.54e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—JUN—sarcoma	9.71e-06	4.54e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CTNNB1—sarcoma	9.63e-06	4.51e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CTNNB1—sarcoma	9.63e-06	4.51e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—HRAS—sarcoma	9.48e-06	4.43e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—HRAS—sarcoma	9.48e-06	4.43e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—HRAS—sarcoma	9.05e-06	4.23e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SRC—sarcoma	9e-06	4.21e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—sarcoma	8.77e-06	4.1e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—HRAS—sarcoma	8.75e-06	4.09e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—HRAS—sarcoma	8.75e-06	4.09e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SRC—sarcoma	8.71e-06	4.07e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SRC—sarcoma	8.71e-06	4.07e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NRAS—sarcoma	8.66e-06	4.05e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—sarcoma	8.48e-06	3.97e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—sarcoma	8.48e-06	3.97e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NRAS—sarcoma	8.38e-06	3.92e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NRAS—sarcoma	8.38e-06	3.92e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MYC—sarcoma	8.07e-06	3.77e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EGFR—sarcoma	7.89e-06	3.69e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MYC—sarcoma	7.8e-06	3.65e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MYC—sarcoma	7.8e-06	3.65e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EGFR—sarcoma	7.63e-06	3.57e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EGFR—sarcoma	7.63e-06	3.57e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KRAS—sarcoma	7.45e-06	3.49e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KRAS—sarcoma	7.21e-06	3.37e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KRAS—sarcoma	7.21e-06	3.37e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—sarcoma	6.63e-06	3.1e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—sarcoma	6.41e-06	3e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—sarcoma	6.41e-06	3e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HRAS—sarcoma	6.34e-06	2.96e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HRAS—sarcoma	6.13e-06	2.87e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HRAS—sarcoma	6.13e-06	2.87e-05	CbGpPWpGaD
